Pemgarda (pemivibart) Receives Emergency Use Authorization (EUA)
On March 22, 2024, the Food and Drug Administration (FDA) issued EUA for Pemgarda for the prevention of COVID-19 for individuals aged 12 and up with moderate to severe immune compromise due to a medical condition or taking immunosuppressive medications or treatments. These individuals are unlikely to mount an adequate immune response to COVID-19 vaccines. Pemgarda is not a substitute for COVID-19 vaccinations.